skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

Selecting GLP-1 agonists in the management of type 2 diabetes: differential pharmacology and therapeutic benefits of liraglutide and exenatide

Review

(2818) Views  (1024) Full article downloads

Authors: Jonathan Pinkney, Thomas Fox, Lakshminarayan Ranganath

Published Date August 2010 Volume 2010:6 Pages 401 - 411
DOI: http://dx.doi.org/10.2147/TCRM.S7313

Jonathan Pinkney1, Thomas Fox1, Lakshminarayan Ranganath2

1Department of Diabetes and Endocrinology, Peninsula College of Medicine and Dentistry, Plymouth, United Kingdom; 2Department of Clinical Biochemistry and Metabolic Medicine, Royal Liverpool University Hospital, Liverpool, United Kingdom

Abstract: Failure of secretion of the incretin hormone glucagon-like peptide-1 (GLP-1) plays a prominent role in type 2 diabetes, and restoration of GLP-1 action is an important therapeutic objective. Although the short duration of action of GLP-1 renders it unsuited to therapeutic use, 2 long-acting GLP-1 receptor agonists, exenatide and liraglutide, represent a significant advance in treatment. In controlled trials, both produce short-term glucose-lowering effects, with the reduction in hemoglobin A1c of up to 1.3%. These responses are often superior to those observed with additional oral agents. However, unlike sulfonylureas, thiazolidinediones, or insulin, all of which lead to significant weight gain, GLP-1 receptor agonists uniquely result in long-term weight loss of around 5 kg, and higher doses may enhance this further. Reduction in blood pressure of 2–7 mm Hg also has been observed. Both drugs produce transient mild gastrointestinal side effects; although mild hypoglycemia can occur, this is usually in combination with other hypoglycemic therapies. However, serious hypoglycemia and acute pancreatitis are rare. The once-daily dosage of liraglutide makes it more convenient than twice-daily dosage of prandial exenatide, and a superior glucose-lowering effect was observed in the only head-to-head comparison reported so far. Besides cost, these considerations currently favor liraglutide over exenatide. Further studies are needed to confirm long-term safety, and most importantly, that short-term benefits translate into long-term reductions of diabetes-related cardiovascular events and other complications.

Keywords: diabetes, weight loss, glycemic control, blood pressure







Readers of this article also read:

Gamma knife radiosurgery for uveal melanoma ineligible for brachytherapy by the Collaborative Ocular Melanoma Study criteria
Redefining the role of thiazolidinediones in the management of type 2 diabetes
Evidence-based decision-making within the context of globalization: A “Why–What–How” for leaders and managers of health care organizations
Radiolucency below the crown of mandibular horizontal incompletely impacted third molars and acute inflammation in men with diabetes
Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors
Anesthesiologists’ perception of patients’ anxiety under regional anesthesia
Erratum - Intracellular heavy metal nanoparticle storage
Erratum
Improvement of adenoviral vector-mediated gene transfer to airway epithelia by folate-modified anionic liposomes
Hepatotoxicity due to tocilizumab and anakinra in rheumatoid arthritis: two case reports